Gleason 3+4 prostate cancer is highly curable. Ten-year cancer-specific survival rates reach 94 to 96%, and the vast majority of men treated with either surgery or radiation therapy are alive and cancer-free a decade later. While no oncologist will use the word “cured” lightly, the numbers for this grade of prostate cancer are among the most favorable in all of cancer medicine.
What Gleason 3+4 Means
A Gleason score combines two numbers representing the two most common patterns a pathologist sees in your biopsy tissue. The first number is the dominant pattern. In a 3+4 score, most of the cancer cells still form recognizable, well-shaped glands (pattern 3), with a smaller portion showing irregular, fused, or poorly formed glands (pattern 4). The total equals 7, but the order matters enormously.
Under the newer grading system adopted internationally, Gleason 3+4 is classified as Grade Group 2 on a 1-to-5 scale. It sits in the “intermediate risk” category, which the American Urological Association further splits into favorable and unfavorable tiers depending on your PSA level, clinical stage, and how many biopsy cores contain cancer. If your PSA is under 10, the tumor is confined to one side of the prostate, and fewer than half of your biopsy cores are positive, you fall into the favorable intermediate-risk group, which carries the best outlook.
How 3+4 Differs From 4+3
Both scores add up to 7, but 4+3 is a meaningfully different disease. When pattern 4 is the dominant component, the cancer behaves more aggressively. A landmark study published in the Journal of Clinical Oncology found that men with 4+3 tumors were about three times more likely to develop lethal prostate cancer compared to men with 3+4 tumors after surgery. That three-fold difference is exactly why the grading system separates them: 3+4 is Grade Group 2, while 4+3 is Grade Group 3. If your report says 3+4, you’re on the more favorable side of that divide.
Survival Numbers After Treatment
The long-term statistics for Gleason 3+4 are reassuring from multiple angles. A large analysis using the SEER national cancer database found five-year cancer-specific survival of roughly 98% and ten-year cancer-specific survival between 94 and 96% for men with Gleason 3+4 tumors. These numbers reflect the reality that most men with this diagnosis will not die of prostate cancer.
After surgery specifically, about half of all prostatectomy patients in large series have a final pathology score of 3+4. While roughly 29% of surgical patients overall experience a rise in PSA at some point (called biochemical recurrence), a PSA bump does not necessarily mean the cancer will become life-threatening. Cancer-specific mortality within ten years of surgery ranges from 2 to 30% across all risk groups combined, with lower-grade tumors like 3+4 clustering at the low end of that range.
Radiation therapy produces similarly strong results. A study of definitive radiation therapy across a national healthcare system reported ten-year metastasis-free survival of 92% for Grade Group 2 patients. That means more than nine out of ten men treated with radiation had no detectable cancer spread a full decade after treatment.
Treatment Options
Current guidelines from the AUA and the American Society for Radiation Oncology recommend three options for favorable intermediate-risk prostate cancer: active surveillance, surgery (radical prostatectomy), or radiation therapy. The choice depends on your age, overall health, tumor characteristics, and personal priorities around side effects.
Surgery
Radical prostatectomy removes the entire prostate gland. It offers the advantage of a definitive pathology report, meaning doctors can examine the whole organ and confirm whether the cancer was fully contained. Recovery typically involves several weeks off work and a period of managing urinary control and sexual function, both of which improve over months for most men.
Radiation Therapy
External beam radiation or brachytherapy (radioactive seed implants) can treat the cancer without surgery. For unfavorable intermediate-risk cases, radiation is typically combined with a period of hormone therapy to improve effectiveness. Treatment courses run from several weeks for external beam to a single procedure for some forms of brachytherapy.
Active Surveillance
Not every Gleason 3+4 cancer needs immediate treatment. NCCN guidelines list active surveillance as an option for men with favorable intermediate-risk disease, specifically those with fewer than 50% positive biopsy cores. ASCO guidelines similarly note that men with low-volume Gleason 3+4 cancer may be considered for monitoring. Active surveillance involves regular PSA tests, repeat biopsies, and often MRI imaging on a set schedule. Treatment is triggered only if the cancer shows signs of progressing. This approach lets some men safely avoid or delay the side effects of surgery or radiation while maintaining the window for curative treatment.
Genomic Testing Can Sharpen the Picture
A Gleason score tells you what cancer cells look like under a microscope, but genomic tests analyze the tumor’s DNA to predict how it will actually behave. Tests like the Decipher classifier have been validated in over 3,000 patients and can identify which tumors are genuinely aggressive and which are more indolent despite looking similar under the microscope.
In practice, genomic testing changes treatment recommendations for about 39% of patients. Men whose tumors score as low or intermediate genomic risk can often safely choose observation after surgery, with recurrence rates similar to those who received additional radiation. Men with high genomic risk scores, on the other hand, are more likely to benefit from early additional treatment. If your doctor recommends genomic testing alongside your Gleason score, it’s because the combination gives a more complete picture than either number alone.
What “Curable” Really Means Here
Oncologists generally consider prostate cancer “cured” when PSA remains undetectable for years after treatment, with no sign of recurrence on imaging. For Gleason 3+4, the overwhelming majority of men reach that benchmark. With ten-year cancer-specific survival above 94% and metastasis-free survival above 90% regardless of whether they chose surgery or radiation, the prognosis is excellent by any standard.
The practical takeaway: a Gleason 3+4 diagnosis is serious enough to warrant treatment planning, but the disease is caught at a stage and grade where the available treatments are highly effective. Most men with this diagnosis will live out a normal lifespan, and many will have multiple good treatment options to choose from.